Publications, Presentations & White Papers

Applications in Theranostics

Perk TG, Weisman AJ, Lokre O, et al. Automated evaluation of disease on 68Ga-DOTATATE PET/CT images for long-term lesion tracking on 177Lu-DOTATATE therapy. Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2022 (Poster Presentation).

Perk TG, Liu G, Starbuck GS, et al. Automated Assessment of 68Ga-PSMA PET/CT Images of Metastatic Prostate Cancer Using Quantitative Total Bone Imaging. The American Association of Physicists in Medicine (AAPM) Annual Meeting 2019 (Poster Presentation).

Nauseef JT, Thomas C, Sun M, et al. Quantitative assessment of PSMA imaging before and after 177 Lu-PSMA-617 treatment in a Ph I/II trial. American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) 2022 (Poster Presentation).

Applications in Immuno-Oncology Therapies

Dell’Oro M, Francis RJ, Gray ES, et al. Application of novel AI-assisted technology in 18F-FDG PET-CT scan analysis – Predicting disease response in metastatic melanoma patients undergoing immunotherapy. Society for Immunotherapy of Cancer (SITC) 2023 (Poster Presentation).

Francis RJ, Dell’Oro M, Gray ES, et al. Application of novel machine learning to predict immunotherapy related toxicities for metastatic melanoma patients from baseline and follow up 18F-FDG PET/CT scans European Society for Medical Oncology (ESMO) Congress 2023 (Poster Presentation).

Simon NI, Columbres, RC, Chandran E, et al. Association of 18F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies. Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) 4600-4600. American Society of Clinical Oncology (ASCO) Annual Meeting 2023 (Poster Presentation)

Hribernik N, Huff DT, Studen A, et al. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging. 2022 May;49(6):1857-1869.

Huff DT, Ferjancic P, Namías M, et al. Image intensity histograms as imaging biomarkers: Application to immune-related colitis. Biomedical Physics and Engineering Express. 2021 Sep 30;7(6).10.1088/2057-1976/ac27c3.

Levi J, Perk T, Huynh L, et al. AI-assisted whole-body assessment of immunotherapy response using [18F]F-AraG, a PET agent for activated T cells. Society for Immunotherapy of Cancer (SITC) 2021 (Poster Presentation).

Muzi M, O’Sullivan F, Perk TG, el al. Whole-Body [18F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687. Tomography 2021, 7(2), 139-153

Heterogeneity of Change

Murthy V, Lokre O, Perk T, et al. Exploring the Generalizability of the Prognostic Value of Machine Learning Models Trained on Mid-Treatment PSMA PET/CT to End-of-Treatment PSMA PET/CT in mCRPC Patients Treated with 177Lu-PSMA Radioligand Therapy Using the TRAQinform Profile: A Retrospective, Single-Center Analysis. PSMA Conference 2024  (Poster Presentation)

Dell’Oro M, Ebert MA, Ong J, et al. Application of Novel Machine Learning Model in [68Ga] Ga-PSMA-11 PET/CT – Predicting Survival in Oligometastatic Prostate Cancer Patients. European Society for Medical Oncology (ESMO) Congress 2023 (Poster Presentation).

Dell’Oro M, Yeung S, Ebert MA, et al. Automated assessment of lesion heterogeneity for metastatic prostate cancer patients using [68Ga]Ga-PSMA-11 PET/CT images. 53rd Annual Scientific Meeting of the Australian And New Zealand Society Of Nuclear Medicine 2023 (Oral Presentation)

Kyriakopoulos CE, Heath EI, Ferrari A, et al. Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide. Journal of Clinical Oncology. 2020;38(31):3662-3671.

Harmon SA, Perk TG, Lin C, et al. Quantitative assessment of early [18F]sodium fluoride positron emission tomography/computed tomography response to treatment in men with metastatic prostate cancer to bone. Journal of Clinical Oncology. 2017;35(24):2829-2837.

McNeel DG, Eickhoff JC, Johnson LE, et al. Phase II Trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP [MVI-816]) in patients with progressive, nonmetastatic, castration-sensitive prostate cancer. Journal of Clinical Oncology. 2019;37(36):3507-3517.

‍Kyriakopoulos CE, Heath EI, Ferrari A, et al.  Interlesional Response Assessment with 18F-Sodium Fluoride (18F-NaF) PET/CT in Men with Chemotherapy-Naive Bone Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide. American Society of Clinical Oncology (ASCO) Annual Meeting 2019‍ (Poster Presentation).

Lin C, Bradshaw TJ, Perk TG, et al. Repeatability of Quantitative 18F-NaF PET: A Multicenter Study. Journal of Nuclear Medicine December 2016, 57 (12) 1872-1879.

Madan RA, Gandhy SU, Karzai F, et al. Analysis of serial PET imaging and paired Tc99 scans in metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide. Annals of Oncology volume 32, supplement 5, S647, European Society for Medical Oncology (ESMO) Congress 2021 (Abstract)

Applications in Computed Tomography (CT) Imaging

Pachynski R, Iannotti N, Laccetti A, et al. A Phase 1 Trial of Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Update From the First-in-Human Study. American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) 2023 (Poster Presentation).

Laccetti A, Pachynski R, Iannotti N, et al. Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer: Results From the First-in-Human Dose Escalation Phase 1a Study. Prostate Cancer Foundation Scientific Retreat 2022 (Poster Presentation).

Automated Lesion Detection and Quantitative Response Assessment of Diagnostic CT Images (White Paper).

Prognostic Biomarkers

Murthy V, Lokre O, Perk T, et al. Exploring the Generalizability of the Prognostic Value of Machine Learning Models Trained on Mid-Treatment PSMA PET/CT to End-of-Treatment PSMA PET/CT in mCRPC Patients Treated with 177Lu-PSMA Radioligand Therapy Using the TRAQinform Profile: A Retrospective, Single-Center Analysis. PSMA Conference 2024  (Poster Presentation)

Dell’Oro M, Francis RJ, Gray ES, et al. Application of novel AI-assisted technology in 18F-FDG PET-CT scan analysis – Predicting disease response in metastatic melanoma patients undergoing immunotherapy. Society for Immunotherapy of Cancer (SITC) 2023 (Poster Presentation).

Francis RJ, Dell’Oro M, Gray ES, et al. Application of novel machine learning to predict immunotherapy related toxicities for metastatic melanoma patients from baseline and follow up 18F-FDG PET/CT scans European Society for Medical Oncology (ESMO) Congress 2023 (Poster Presentation).

Dell’Oro M, Ebert MA, Ong J, et al. Application of Novel Machine Learning Model in [68Ga] Ga-PSMA-11 PET/CT – Predicting Survival in Oligometastatic Prostate Cancer Patients. European Society for Medical Oncology (ESMO) Congress 2023 (Poster Presentation).

Simon NI, Columbres, RC, Chandran E, et al. Association of 18F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies. Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) 4600-4600. American Society of Clinical Oncology (ASCO) Annual Meeting 2023 (Poster Presentation)

Perk TG, Yip SSF, Weisman AJ, et al. Incorporation of intrapatient response heterogeneity using 18 F-NaF PET/CT imaging improves outcome prediction models for metastatic prostate cancer patients. Journal of Clinical Oncology.2022;40(16_suppl):e13554.

Liu G, la Fontaine M, Weisman AJ, et al. Comprehensive assessment of 18F-FDG PET/CT images of cancer patients improves predictions of survival. European Society for Medical Oncology (ESMO) Congress 2022 (Poster Presentation).

Varghese D, Kimia SA, Lokre O, et al. Application of a Novel Machine Learning Model in Predicting Survival in Adrenocortical Cancer (ACC). European Society for Medical Oncology (ESMO) Congress 2022 (Poster Presentation).

Muzi M, O’Sullivan F, Perk TG, el al. Whole-Body [18F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687. Tomography 2021, 7(2), 139-153.

Non-oncology Applications

Weisman AJ, Martin E, Heidel RE, et al. Fully Automated 3D Segmentation and Quantitation of the Amyloidophilic Radiotracer Iodine Evuzamide (124I-p5+14, 124I-AT-01) in the Heart of Patients with Systemic Amyloidosis and Healthy Subjects. The American College of Cardiology (ACC) Annual Scientific Session & Expo 2022 (Poster Presentation).

Weisman AJ, Martin E, Heidel RE, et al. Automated Segmentation and Quantitation of PET/CT Images Using 124I-p5+14 (AT-01) in Patients with AL and ATTR Amyloidosis. World Molecular Imaging Congress (WMIC) 2021 (Poster Presentation).

Technology Development

Wangerin K, Miller R, Battle M, et al. Automated Lesion Detection for 18F-Fluoroestradiol PET/CT Images Demonstrates Lesion Heterogeneity in Patients with ER+ Metastatic Breast Cancer. 36th Annual Congress of the European Association of Nuclear Medicine (EANM) 2023 (Poster Presentation)

Lokre O, Weisman AJ, Munian-Govindan R, et al. Cross-radiotracer generalizability of automated lesion detection via CNN: pilot study in 64Cu-and 68Ga-DOTATATE PET/CT. Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI) 2023 (Oral Presentation)

Dell’Oro M, Yeung S, Ebert MA, et al. Artificial intelligence in medical imaging–industry collaboration enabling advanced analysis of disease burden in patients with metastatic prostate cancer to improve individualized treatment. Science on the Swan 2023 (Oral Presentation)

Lokre O, Weisman A, Perk T, Comparison of Physiologic FDG PET Uptake in CT-Based Vs PET-Corrected Organ Contours in Non-Small Cell Lung Cancer Patients. The American Association of Physicists in Medicine (AAPM) Annual Meeting 2022 (Oral Presentation).

Santoro-Fernandes V, Huff DT, Scarpelli ML, et al. Development and validation of a longitudinal soft-tissue metastatic lesion matching algorithm. Physics in Medicine & Biology. 2021; (111):0-13.

Weisman AJ, Lokre O, Schott B, et al. Automated detection and quantification of neuroendocrine tumors on 68Ga-DOTATATE PET/CT images using a U-net ensemble method. Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI) 2022 (Poster Presentation).

Weisman AJ, la Fontaine M, Lokre O, et al. Impact of Combining Training Data from Multiple Disease Types On Lesion Detection Performance in Two CNN Architectures. The American Association of Physicists in Medicine (AAPM) Annual Meeting 2022 (Poster Presentation).

Weisman AJ, la Fontaine M, Lokre O, Munian-Govindan R, Perk T. Determination of Generalizability for CT Organ Segmentation CNNs Across Scanner Manufacturer. The American Association of Physicists in Medicine (AAPM) Annual Meeting 2022 (Poster Presentation).

Information on this page is intended for research use only. Not all applications and/or claims listed are currently cleared for use in treatment of patients. TRAQinform IQ software has been cleared by the FDA for clinical use under 510(k) K173444.

Alessandra Cesano, MD, PhD
Chief Medical Officer, ESSA Pharma

Alessandra Cesano, MD, PhD is the Chief Medical Officer at ESSA Pharma since July 2019. Previously she has been the Chief Medical Officer of NanoString Inc from July 2015 until June 2019 where she focused in the development of translational and diagnostic multi-plexed assays for the characterization and measurement of mechanisms of immune response/resistance. Prior to joining NanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc. and before then she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the R and D group, while providing the overall clinical vision for the organization. Between 1998 and 2008, Dr. Cesano held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals. Early in her professional career Dr. Cesano spent 12 years conducting research in tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center connected with the University of Pennsylvania. She also holds membership in several professional and scientific societies including ASCO, ESMO, ASH, EHA, AACR and SITC. In the latter she serves as co-chair in the SITC Industry Committee, Associate Editor for the Biomarker section of JITC and is an active member of the SITC Biomarker Working Group. Over her careers she has been an author on over 140 publications. Dr. Cesano received an MD summa cum laude, a Board Certification in Oncology and a PhD in Tumor Immunology from the University of Turin.

This will close in 40 seconds

Giovanni Selvaggi, PhD
Chief Medical Officer, Xcovery

Dr. Selvaggi held global positions of increasing responsibility in clinical development at various global pharmaceutical companies prior to joining Xcovery in March 2019. Dr. Selvaggi joined the pharmaceutical industry in 2010 as Medical Director in the MAGE-A3 lung cancer vaccine program at GSK. He then played an instrumental role in the successful development and approval of ceritinib (Zykadia) in ALK-translocated NSCLC at Novartis in 2013. Most recently, Dr. Selvaggi was part of the immunotherapy team at Bristol-Myers Squibb, serving as a program lead in thoracic malignancies, with a focus on SCLC and mesothelioma, leading to the approval of nivolumab (Opdivo) in third line SCLC indication with NDA in 2018. Dr. Selvaggi received his medical degree at the University of Torino School of Medicine, in Torino, Italy, in 1992 and served as staff physician of thoracic oncology at the University Hospital in Torino, participating in several clinical trials in lung cancer and mesothelioma over a span of 16 years.

This will close in 40 seconds

Eric Horler
President and Chief Executive Officer, AIQ Solutions

Eric Horler joined AIQ Solutions as its first President and CEO in September 2018. He has led AIQ through two rounds of equity financing, team construction, product commercialization, and international expansion. Before joining the AIQ team, Eric was President and CEO of Swallow Solutions LLC, a medical device start-up with both therapeutic devices and functional beverages for dysphagia patients. Before that, Eric was General Manager, Premium Anesthesia and Respiratory Care at GE Healthcare. While at GEHC, Eric was responsible for a $220 million global business and a large team spread over three continents. He has also held a series of marketing and business development roles at Baxter Healthcare, including Director of Renal Products and Services for the Latin America region. Eric has a B.S. in Chemical Engineering from Rice University and both an MBA and Master of Engineering Management degrees from the Kellogg School of Business. He lives in Madison with his wife and two children.

This will close in 40 seconds

Information on this page is intended for research use only. Applications and/or claims listed are not currently cleared for use in treatment of patients.